# **UDS** Console: Today and Tomorrow

An opportunity to modernize, integrate, improve ...

April 2022



# Introduction



#### Matt Duffy

Sr. Director, Product Management, Regulatory Reporting MDuffy@nextgen.com



#### Joy Snyder

Product Manager, Clinical Specialist



# UDS+ Updates

- Tracking Quality Measures Available Now!
- What Else Is Coming This Year
- The "Vision"
- Show and Tell
- Q&A



# UDS Modernization Initiative (UDS+)



# UDS Modernization (aka UDS+) - 1 of 2

- The basics\*
  - Why the change?
    - "HRSA aims to reduce reporting burden, improve data quality, and better measure program services and outcomes."
  - What is the change?
    - A redesigned section of the UDS report replacing existing patient-oriented aggregated tables with de-identified patient-level data
  - When is this happening?
    - HRSA is targeting the 2023 UDS report, due Feb/Mar 2024
  - How is HRSA doing this?
    - "Plans are underway to enable UDS+ reporting via FHIR."
      - FHIR is **not** required for UDS+. FHIR will be one of two options for submitting UDS+ data. HRSA plans to accept UDS+ data through either a manual file upload system (i.e., traditional HL7 or CSV) or FHIR interface.

\*Source: HRSA Uniform Data System (UDS) Modernization Initiative website: UDS+



### UDS Modernization (aka UDS+) - 2 of 2

- What is NextGen doing to prepare?
  - Reinforcing our investment
    - FHIR/API ready we are ready when HRSA is
    - Addition of new resources, near doubling of our development and product leadership team
    - Platform modernization and integration
  - Communicating with HRSA
    - Conversations with key stakeholders at HRSA (Judy Van Alstyne's team) continue
  - Communicating with clients via User Groups and with HCCNs
    - NACHC, CCALAC, CPCA, OSIS



# UDS Console Focus ... We are at Work!





# UDS Reporting Advancements – Available Now

### **Primary Problem Identified**

- Limited ability to monitor quality measures throughout the year
- Delays in access to current year measure specifications
- Inability to implement process changes that impact quality

### **Targeted Solution**

- Continuous monitoring throughout the year based on <u>current</u> 2022 specifications
- Provider comparison, goal tracking
- Dynamic drill down & visualizations
- Pursuit list integration with NG Care Hub
- Recommendations at the point of care



# **UDS Reporting Advancements - Detail**

#### Leveraging HQM

- A new program, UDS Trending, has been added to HQM – NextGen's ONC certified measure platform
- Data is updated weekly (or more often if needed)
- Measures based on current CMS 2022 specifications
- Cloud solution: web portal, no software installation required

### Measures Currently Available

- CMS 2v11 (NQF 0418e) Depression Screening and Follow Up
- CMS 69v10 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
- CMS 117v10 Childhood Immunization Status
- CMS 138v10 (NQF 0028e) Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
- CMS 155v10 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents
- CMS 349v4: HIV Screening
- CMS 122v10 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
- CMS 124v10 Cervical Cancer Screening
- CMS 125v10 Breast Cancer Screening
- CMS 130v10 Colorectal Cancer Screening
- CMS 159v10 (NQF 0710e) Depression Remission at Twelve Months
- CMS 164v7 (NQF 0068) IVD: Use of Aspirin or other Antiplatelet
- CMS 165v10 Controlling High Blood Pressure
- CMS 347v5 Statin Therapy




# UDS Reporting Advancements – In process for Q2 and Q3

- Additional Measures (non-eCQMs)
  - Dental Sealants for Children between 6-9 Years
  - HIV Linkage to Care
  - Section A: Prenatal Care Age Categories and Demographic Characteristics
  - Section B: Early Entry into Prenatal Care
- Measure Updates
  - Measures will be updated with the 2022 HRSA ruling



# A New UDS Console: Integrated with HQM



Confidential - Proprietary Information - For Internal Use By Authorized Company Employees Only. Do Not Distribute.

### What Does This Mean for the UDS Console?

- The "legacy" UDS Console will be updated to support 2022 reporting
  - HRSA updates will be incorporated, on-time delivery pre UGM in 2022
  - Clients will use the solution for their February 2023 UDS deadlines
- The legacy UDS Console will be retired after the February 2023 season
  - No updates for 2023 will be made to the existing console
  - There will be no surprises!
- From a client's perspective, no change to our commitments
  - A UDS reporting solution remains mission critical for NextGen
  - We are committed to a modernized, integrated platform



# **BELIEVE IN BETTER**<sup>®</sup>



# Track Quality Performance – Compare to Goals and Benchmarks



2021, Evaluation Date: 3/26/202			Patient	s In		(	Performance	Goal	Ben	Nat. chmarks
Measure	IPP	DEN	NUM	EXCP	EXCL	то	Rate (%)	(%)	Current Dec.	10th Dec.(%)
CMS 50v9 Closing Referral	3939	3939	438	0	0	3501	87.58	59.00	7	>= 89.66
CMS 142v9 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	35	14	0	0	0	14	0.00	0.00	0	>= 97.88 mance
CMS 2v10 (NQF 0418e) Depression Screening and Follow Up	13183	13183	9729	0	2224	1230	88.78	80,00	perfor	mance
CMS 22v9 BP Screening and Follow Up	27317	27317	8169	0	13244	5904	58.05		-	-
CMS 69v9 Preventive Care and creening: Body Mass Index BMI) Screening and Follow-Up Ian	11530	11530	9058	0	1188	1284	87.58	59.00	-	
CMS 75v9: Children Who Have Dental Decay or Cavities	0	0	0	0	0	0	0.00	0.00	10	0
CMS 117v9 Childhood mmunization Status	191	191	22	0	0	169	11.52	80.00	0	>= 56.86
CMS 127v9 Pneumococcal /accination Status for Older dults	1245	1245	849	0	0	396	68.19	70.00	-	-
CMS 138v9 (NQF 0028e) Tobacco Use Screening and Cessation	7732	7732	7205	0	0	527		83.00		
CMS 138v9 NUM1	7732	7732	7205	0	0	527		83.00		
MS 138v9 NUM2	7732	2780	1943	0	0	837	69.89	83.00	-	
IS 138v9 NUM3	7732	7732	6453	0	0	1279		83.00		
INS 147v10 (NQF 0041e)	15907	8484	1557	341	0	6586	19.12	0.00	-	-



Confidential - Proprietary Information - For Internal Use By Authorized Company Employees Only. Do Not Distribute.

# Track Quality Performance – Compare to NextGen Population

5	Measure Name	Goal(%)	Actual(%)	Variance	Status	NextGen Average	Performance Analy
							Perform
	CMS 122v9 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)	20.00	32.95	12.95	<u>Not Met</u>	64.35%	
	CMS 124v9 Cervical Cancer Screening	85.00	46.07	(38.93)	Not Met	15.02%	
	CMS 125v9 Breast Cancer Screening	60.00	25.73	(34.27)	Not Met	19.68%	
	CMS 128v9 Anti- depressant Medication Management	60.00	0.00	(60.00)	Met	4.43%	
	CMS 130v9 Colorectal Cancer Screening	50.00	8.20	(41.80)	Not Met	22.43%	
	CMS 131v9 Diabetes: Eye Exam	90.00	0.00	(90.00)	Not Met	31.91%	

# **Provider Performance Stratification**

		CMS 125v9 Breast Cancer Screening	CMS 124v9 Cervical Cancer Screening	CMS 130v9 Colorectal Cancer Screening		
		CMS 125v9 Breast Cancer Screening	CMS 124v9 Cervical Cancer Screening	CMS 130v9 Colorectal Cancer Screening		
Providers	Measure End Date: 12/31/2021	Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer in the 27 months prior to the end of the Measurement Period.	Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria: * Women age 21-64 who had cervical cytology performed within the last 3 years * Women age 30-64 who had cervical human papillomavirus (HPV) testing performed within the last 5 years	had appropriate screening for colorect. cancer	Measures	
6		34.14 % (1000 / 2929)				
	Dr Gloria Anton	25.73 % (53/206)	46.07 % (211/458)	8.2 % (26/317)		
	Dr Sam Bird	34.14 % (1000 / 2929) 25.73 % (53/206) 19.01 % (23/121) 26.09 % (90/345)	52.61 % (141/268)	14.58 % (28/192)		
	Dr Chris Bridgewater	26.09 % (90/345)	36.45 % (242/664)	6.5 % (39/600)		
	Dr Chris Carson	43.15 % (145/336)	34.64 % (229/661)	14.19 % (86/606)		
	Dr Matthew Klein	33.33 % (1/3)	0 % (0/3)	33.33 % (1/3)		
	Dr Oswald Kramer	0 % (0/0)	0 % (0/0)	0 % (0/0)		
	Dr Geoff Larson	20.22 % (55/272)	47.26 % (276/584)	4.52 % (21/465)		
	Dr Jill Monroe	0 % (0/0)	0 % (0/0)	0 % (0/0)		
	Dr Cindy North	38.64 % (182/471)	39.65 % (364/918)	3.36 % (25/744)		
	Dr Sandra Omar	0 % (0/0)	0 % (0/0)	0 % (0/0)	povtgo	

Confidential - Proprietary Information - For Internal Use By Authorized Company Employees Only. Do Not Distribute.

# Leveraging NextGen Care Hub for Actionable Insights


Cohorts List Nam * A1c * Dr. Jen * Wellnes	Gen Care® Popula s 🔯 Filter 🔠 My List								RX		- 🥌 🏹 🦻	🍒 i 🚳 🌾 🔅		
Cohorts List Nam * A1c * Dr. Jen * Wellnes	s 🔯 Filter 🔠 My List ne		nt Jo	-	0 - 1									<
List Nam * A1c * Dr. Jen * Wellnes	ie	s ESchedule		-						-				
* A1c * Dr. Jen * Wellnes					I. Selec	t Cohort L	ist (Patier	nts with Ti	reatment (	Gaps)		Care Opportunities		0
* Dr. Jen * Wellnes	Fix Patients		PHS	- non-	sauers, briar	07/29/2021	sauers, brian	,	09/27/2021			Patient	Settings: Peds <mark>▼</mark> <u>Print</u>	
			1110		sauers, brian		sauers, brian		09/23/2021			DOB: Home Phone:	1	
*Patient's	ss Overdue				sauers, briar		sauers, brian		06/1/2021			Cell Phone:	1	
	s Not Seen		PHS		sauers, briar	08/23/2021	sauers, brian		2021			Email:	1	
	ancer abnormal		PHS		sauers, briar	07/07/2021	sauers, brian		_021			Language:	Portal Enrollment:	
	ancer Screening		PHS		sauers, briar	07/02/2021	sauers, brian	Patient List ppointment ▼ H	//02/2021	IEW Patient's S153.00 \$558.00	nan	Provider:	1	
COVID H	ligh Risk				sauers, briar	06/16/2021	sauers, brian	ant Lis	07/02/2021		CUI	Primary	1	
📘 🖬 My Li	ist: * Depres	ssion Scree	ning Fo	llow Up	Required			natier.		nt's		Insurance: Last Encounter:	1	
Patients:							une.	ra		atien		Smoking Status:	1	
□ ∇ ▼	Patient Name 🛛 🌣	Date of Birth	⊽ Sex ⊽	Pref Lan		Last Encount 🗸 🤇	Cell re the	ppointment 🛛 H	ome Phone 🛛 🏹	P'O Appo	ointment Provider ⊽	F Race:	1	
	Miller, John	11/03/1948	Male			09/02/2019	0101			ICN		Ethnicity:	1	
	Vidmar, Johnny	10/16/1965	Male		55 years	02/13/20	XP	(5	555) 555-* B.	\$153.00		Current Gender:	1	
		01/10/1950	Male		71 years	081		14	J.	\$558.00		Sexual	1	
	Lang, Mark Axel, Calvin	04/22/1978 05/19/1988	Male Male		43 year 33 year			ſe		\$548.00		Orientation:	1	
	Tingstead, Tracy		Female	English	43 years	24/2019			+5-6353	\$3,875.00		Preferred Pronoun:	1	
		09/14/1969	Male	English	52 years	09/09/2019			+) 983-4837	\$372.16		Gender Identity:	1	
	Vanhoosier, Mich	11/11/1978	Male	English	42 years	09/24/2019		(8	806) 796-8463	\$1,674.00		Next Appointment		
												- Details		
												Location:	· · · · · · · · · · · · · · · · · · ·	
												Resource:	· · · · · · · · · · · · · · · · · · ·	
												Event Type:		
													1	
													1	
									4.Take A	111			1	
										-tion :			1	
									A	Cur			1	
									. Take.				1	
									4.10				1	
													1	
													1	
					111							>	· · · · · · · · · · · · · · · · · · ·	
	✓ Order Rec	all Message -				Alert Import	Export - Schedu					- L		

NextGen Medical Group 👤 bsauers 🔤 CAP NUM SCRL 09/27/2021

R 🐫

9:32 AM 9/27/2021

 $\Box$ 



# At the Point of Care, Treatment Recommendations

	Admin Utilities Window Help	<b>7</b> // 💁 🙈	🔁 🗹 📧 🐜 🕺 📕 🔄 🚸 姜 🤣	s a 🕅 🕅
Main Office	Barclay, Joseph B M.D. Save Cl	ose Clear Close Patient Patient	History Inbox Templates Images Medications Orders Documents Medication Allergies PAQ PM	DM Dashboard EDR Proce
Branam (F) DOB: 01/25	🚈 Patient Quality Reporting		am 🛛 Total Treatment Opportunitie 🗕 🗖 👂	Lab Results 💿
Address: 300 Troll Rocheste	2021 eCOM Group 2021 eCOM Individual 2021	MIPS CQM Group		
Contact: (585) 99	Information displayed is ci		orts on the period from 1/1/2021 to	Gaps in Ca
08/23/2021 10:00 AM : *	Measure #	Status	Measure Description	C362
Specialty Internal Medicine	CMS 125v9 Breast Cancer Screening	Treatment Opportunity	Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer in the 27 months prior to the end of the Measurement Period.	© Settings
Care Guidelines (1) The Intake atient Tracking Adult	CMS 156v9 Use of High-Risk Medications in Older Adults	Treatment Opportunity	Percentage of patients 65 years of age and older who were ordered at least two of the same high-risk medications.	=
General Informatio	CMS 122v9 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)	Performance Met	Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period	
Enter/Select Historian			Percentage of patients 18-75 years of age with diabetes	
Reason for Visit	CMS 131v9 Diabetes Eye	Performance Met	and an active diagnosis of retinopathy overlapping the measurement period who had a retinal or dilated eye exam by an eye care professional during the measurement period or diabetics with no diagnosis of retinopathy	Health Promotion P
Chronic Conditions	Exam		overlapping the measurement period who had a retinal or dilated eye exam by an eye care professional during the measurement period or in the 12 months prior to the measurement period.	Office Diagnostics
Collapse All Expand			Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 12 months AND who received tobacco cessation intervention	~

Confident Cough

### Plans to Modernize Point of Care Insights

NextGen® Enterprise EHR: Emily Branam (Female) DOB: 01/29/1950 AGE: 71 years 6 months PHONE: (585) 999-9	999 - 08/23/2021 10:00 AM : *SOAP	8	Back
	x Templates Images Medications Orders Documents Medication Allergies PAQ PM DM Problems (6) Clagnos (45) (Medications (5) (Appointmer (10) Clata Share	-	Emily Branam 71 yrs DOB 01/29/1950 PHS Patient
Address: 300 Trolley Blvd Pt. Insurance: Medicare Part B Pharm: CA Pharmac Rochester, NY 14608 Preferred Name: EDH Program: Contact: (585) 999-9999 (H) Patient Portal: 1 CCM Status: Enrolled COM Status: Enrolled CCM Status: Enrolled	Peferring:	Passed Ga	Launch NextGen PHS
Order Search Q Favorites Immunizations	Ribbon easily docks and expanded	Near Due C	PAST DUE GAPS FAILED GAPS RISK SCORES
08/23/2021 10:00 AM : "Home Page"       08/23/2021 10:00 AM : "SOAP ×         Specialty       Office Visit ▼         Established/New       ●         Show Risk Indicators       ●	Salir fisk scoring	Past Due G	Medicare Annual Wellness Visit (AWV) Custom (65+)
↑ Intake Histories SOAP Finalize Checkor	Risk Level O Care Team	Failed Gap	Result Value Past Patient has not received an annual Due wellness visit.
✓ General Information		۵	Colorectal Cancer Screening CMS130v9
Enter/Select Historian	Save		Result Value Past No screening in compliance
Reason for Visit   Intake Comments	Vital Signs () & Orthostatic Vital Signs	Health	Due timeframe.
Chronic Conditions Standing Orders Comment	show more 🗸		Breast Cancer Screening UDS 2020
Introduction: This 71 year old patient presents for Cough.	Physical Exam	Offi	
Select HPI V Favorites V Collapse All Expand All	One Page Exam OR Select Other Physical Exams V Favorites V		Result Value Past No screening during measurement Due period
Cough			



Q1: Is it true that with HQM I will need to join NextGen's "data sharing" program?A1: No client is required to participate in NextGen's "data sharing" programs.



LEGAL NOTICE: This document contains information that is confidential and proprietary to NextGen Healthcare, Inc. and its subsidiaries and affiliates ("Company") and is intended for use solely by its authorized employees. This document may not be copied, reproduced, published, displayed, otherwise used, transmitted, or distributed in any form by any means as a whole or in any part, nor may any of the information it contains be used or stored in any information retrieval system or media, translated into another language, or otherwise made available or used by anyone other than the authorized employee to whom this document was originally delivered without the prior, written consent of Company.

By retaining or using this document, you represent that you are a Company employee who is authorized to use this document and that you will use this document and the information it contains solely as and to the extent permitted by the Company. Any other use or distribution of the contents of this document, as a whole or in any part, is prohibited.

Although we exercised great care in creating this publication, Company assumes no responsibility for errors or omissions that may appear in this publication and reserves the right to change this publication at any time without notice.

© 2021 NXGN Management, LLC. All Rights Reserved.

The registered trademarks listed at www.nextgen.com/legal-notice are the registered trademarks of NXGN Management, LLC. All other names and marks are the property of their respective owners.

Our issued and published patents can be found at www.nextgen.com/legal-notice.

